Visualize live-cell function at scale. CytoTronics is commercializing technology emerging from the Harvard University labs to bring unique insights to drug discovery. A revolutionary approach to studying cell biology, powered by microchips. Electrophysiology, CMOS, Phenotypic Screening, Electrochemistry, Cell measurement, and Cell manipulation

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. The company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cord, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Biotech Company 100% Focused On Advancing New Therapies For Childhood Cancer A life science company exclusively focused on finding cures for childhood cancer by identifying and developing the most promising projects to create new treatments and drugs. drug development, clinical development, and childhood cancer

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to discover, develop and deliver next generation cancer therapies. G1 Therapeutics, Inc. is a wholly owned subsidiary of Pharmacosmos. Cancer / Oncology, Drug Discovery and Development, and Biotechnology

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

167 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We turn medical devices into clinical reality Neo-Bionica bridges the gap between research and the clinic, providing world-class engineering expertise and links to leading clinicians to create life changing medical device solutions. Offering end-to-end medical device prototype development, from initial concept and rapid prototyping, to pre-clinical testing and first-in-human prototypes for clinical trials

120 similar entities Type: Startup Activities: deeptech healthtech biotech manufacturing Technologies: Synthetic Biology

Innovating for cancer patients METHYS Dx develops innovative liquid biopsy tests for non-invasive monitoring of cancer patients. Combining unique proprietary molecular signatures and a disruptive ultrasensitive detection technology, METHYS Dx tests will allow monitoring of tumor evolution, and early detection of relapses, thus improving patient care through better-informed therapeutic decisions. ctDNA, Cancer, Biomarqueurs, circulating tumoral DNA, Liquid biopsy, Precision medicine, and ddPCR

13 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Unlocking the potential of solid samples in the field of biological diagnostic Diagante develops a solution for in vitro diagnostics. Its platform allows the analysis of solid clinical specimen on rapid and high throughput instruments in clinical pathology labs. It provides faster results, enhanced personalized medical care, and lower costs to the stakeholders.

75 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ready -to -use cell bank, for research, for patients Lymphobank - Bank of ready -to -use cells, for research, for patients. Lymphobank is a biotech specializing in the supply of adult and placental -use -for -use blood cells, the characteristics of which will be available online (www.lymphobank.fr), allowing the cellular product to be chosen according to an interest donor. Our services are focused on the development of cellular immunotherapy products. In addition, Lymphobank develops an innovative approach to allogenic adoptive immunotherapy of hepatocellular carcinoma (the most frequent liver cancers and second cause of cancer death in the world, with nearly …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

207 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

For a reliable liquid biopsy accessible to everyone Precision medicine is the adaptation of a medical treatment to the exact molecular profile of each patient. More generally, it relies on the sophisticated analysis of circulating biomarkers (genetic, protein or cellular) in the blood flow of patients. SmartCatch arises from a research work initiated in 2012 by a team of multidisciplinary scientists from the Laboratory of Analysis and Architecture of Systems (LAAS, CNRS) and urologist surgeons of the IUCT-Oncopole and Toulouse hospital. The results of this work have been patented in February 2015. Carried by four of its inventors, SmartCatch was …

6 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

a NOVARTIS company CELLforCURE gathers all cell and gene therapies activities of the LFB group. With an annual production capability of several thousands of therapeutics batches, the Les Ulis CELLforCURE facility is the first modular entity in Europe to enable large scale industrial production for ATMPs. This platform operates on a mixed model of a CDMO (Contract Development and Manufacturing Organisation) providing large scale GMP and cGMP production services, for both clinical and commercial needs, and of a pharmaceutical company leading the development of cell and gene therapies medicinal products up to their launch on the market. CELLforCURE is an …

87 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

Cellvax, founded in 2001, is a preclinical biotech company which provides in vitro and in vivo studies allowing accelera Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products. Preclinical studies CRO, Animal models, Cancer, Osteoarthritis, Bio-markers, …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A French liquid biopsy technology dedicated to the isolation of circulating tumor cells (CTCs) The number of cancer cases continues to rise worldwide, and detection is occurring earlier and earlier. In this context, precision medicine is no longer optional — it has become essential. Tailoring treatments to the specific characteristics of each patient is key to improving survival rates and quality of life. ScreenCell® is fully committed to this approach by developing single-use devices designed to isolate circulating tumor cells (CTCs) from a simple blood sample. Our liquid biopsy technology offers a non-invasive and cost-effective alternative for accessing valuable insights …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

520 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

BioCytex is a contract research organization specializing in biomarker detection and analysis of normal and pathological cells in whole blood, bone marrow and other tissue samples. With over 20 years of experience in flow cytometry, we have a wide range of experience in developing and validating assays to suit many different requirements including immunophenotyping, detection of intracellular / extracellular markers, antigen binding assays. With the capacity to simultaneously measure multiple parameters on hundreds of individual cells per second, flow cytometry is a powerful technology with a wide variety of applications in pharmaceutical development. BioCytex is working with worldwide pharmaceutical companies. …

14 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

294 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dyameo is a research company & amp; Development in the field of medical devices which designs aid probes for the diagnosis of in-vivo cancer cells. This medical device, makes it possible to answer the question: "Are these cells cancerous?", And that in a simple, clear and instant manner. This rupture solution proposes to discriminate cancer cells at an early stage, during endoscopic examinations. Medical devices, medtech, and help with in-vivo cancer diantics

63 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Cell Culture Monitoring Instruments IPRASENSE revolutionizes cell analysis with innovative technologies for automated cell counting and real-time visualization, ideal for research and quality control. Cell culture monitoring, Lensless Lensfree Imaging, Video microscopy, Time lapse Imaging, Automatic cell count and viability analysis, High throughput cell, Inside your incubator, cell count, cell counting, cell viability, cell viability analysis , cell monitoring, and angiogenesis

103 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A Shimadzu Group Company Bimaneo specializes in the design and marketing of innovative medical analysis kits based on the fine analysis of mass spectrometry proteins for neonatal screening and the diagnosis of various pathologies in hospital laboratories. Screening and diagnosis, mass spectrometry, medical device, and biological markers

158 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovative science to improve the health of patients To adress the unmet need to dispose of relevant tools to value the efficacy of treatments for red blood cell disorders, INNOVHEM has developed two important and unique innovations :a simple and accurate method to quantify fetal hemoglobin in each red blood cell and a specific new method to measure intravascular hemolysis. Together with several generic biological assays, INNOVHEM offers a comprehensive and innovative platform that supports the development of new treatments for red blod cell pathologies, from preclinical to phase IV evaluation.

15 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Early cancer detection in blood AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. Biotechnology, Cancer Diagnostics, Innovation, Personalized medicine, Blood test, and Biomarkers

81 similar entities Type: Startup Activities: biotech deeptech

Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation

206 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

54 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

First Swiss Liquid Biopsy for the early detection of cancer based on a new innovative transformational biomarker About 4D Lifetec AG 4D Lifetec is a pioneer on a mission to revolutionize early cancer detection. Our easy and powerful blood tests can detect cancer at its earliest stages (I and II), offering you peace of mind and proactive well-being protection. Sophisticated artificial intelligence (AI) enhances our immunological high-throughput blood assays which in turn enables timely intervention and treatment. Molecular Diagnostics, Oncology, Genotoxicity, DNA Damage and Repair, Liquid Biopsy, Biomarker, Early cancer detection, Early cancer diagnosis, Cancer test, Lung Cancer, and Bronchoscopy

13 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I.

For more information, please visit www.gna-bio.com Laser PCR, Molecular Diagnostics, OEM, Molecular Technology, Biosecurity, Life Sciences, Food Safety, Nucleic Acid Amplification, Molecular Assays, Biotechnology, and Nanotechnology

265 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Pioneering a new era in precision medicine for women's health A clinical-stage biotechnology company pioneering a female-focused precision medicine approach using validated biobanks for the discovery, development, and commercialization of novel therapeutics and companion diagnostics in women's health. ovarian cancer, endometrial cancer, fibrosis, endometriosis, post surgical adhesions, surgery, women's health, fitness, health, lifestyle, precision medicine, Artificial Intelligence, Machine Learning, Biobank, gynecology, reproductive medicine, infertility, cervical cancer, pcos, femtech, life sciences, and healthcare

245 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology A.I.

Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK

119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Providing essential, standardized tools to accelerate breakthroughs in human health Microfluidics | Cytometry | Imaging Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

184 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

131 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

An evolution in cell line engineering. High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

171 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We give access to the pulse of life Unlocking the Future of Cell Screening with Groundbreaking Innovation MicroOmix is a pioneering startup powered by patented technology from the CNRS and the University of Strasbourg, setting a new standard in high-throughput cell screening. Our cutting-edge platform analyzes cells based on the molecules they secrete, with a level of precision and resolution that is unrivaled. Secreted molecules are at the heart of critical biological processes—driving immune responses, cell migration, tissue regeneration, and differentiation. Emerging research reveals their pivotal role in disease progression and therapeutic effectiveness, but until now, accessing these insights has …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Bioscibex, we are redefining bioprocessing with innovative single-use bioreactor solutions tailored for modern biologics and cell therapy manufacturing. Our mission is to empower researchers and manufacturers with tools that simplify processes, enhance scalability, and improve efficiency.

260 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

131 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Let's Build Better Cells Together We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, …

313 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient. Cell Reprogramming, Cancer Immunotherapy, and …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Automation and standardization of cryopreservation processes for Cell Therapies Cellulis (formerly ZF Biotox) provides disruptive cryopreservation technologies in a broad range of biotechnology fields aiming to innovate CELL THERAPY solutions, to streamline BIOPROCESSING production, to enhance BIOBANKING and to improve High Throughput Screening (HTS) campaigns. Frozen Cells in Microplates Ready to Use., Final product formulation for cryopreserved cell therapy, and Cryopreservation of Cell Therapies

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Lab-in-a-cell-devices Dynamic film about cell sensing SPAchip® technology is based on intracellular silicon microchips printed with multiple fluorescent probes to analyse and monitor cellular pathways at real time intracellular processes. The cell-based assays based on SPAchip® are compatible with High Content Screening platforms and imaging analysers. Suspended planar arrays, single cell analysis, cell signaling, flow cytometry, vaccines, and immunothepary

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Acquired by Evotec SE in July 2022, Rigenerand is now operating as Evotec (Moderna) Srl. Originating as a start-up from the University of Modena and Reggio Emilia developing and producing innovative products for pre-clinical and clinical applications of cell-based technologies for regenerative medicine and oncology, the cell technology company aims to fill therapeutic gaps for the many still incurable diseases by manufacturing smart treatments based on gene-modified cells with a specific focus on cancer With its team of leading cell therapy experts, Evotec (Moderna) adds a high-quality cGMP manufacturing site to the EVOcells platform increasing capacity, critical expertise, and capabilities …

125 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

The platform for creating organs and tissues in the lab. The platform for creating organs and tissues in the lab. Biotechnology, Biomaterials, Bioprinting, 3D Cell Culture, Tissue Engineering, Hydrogels, Regenerative Medicine, Research, and Tissue Culture

113 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Platform to engineer cancer killing viruses using synthetic biology. Humane Genomics is developing a platform to engineer cancer killing viruses with unprecedented specificity and efficiency. Our first indication is liver cancer. We are based in New York City and backed by amazing investors. (YC S21)

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Precision Drugs against Eucaryotic Pathogens ASTRA Therapeutics is a Drug Discovery company with a mission to design and develop novel, precision engineered drugs against a whole range of Eukaryotic Pathogens.

505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

170 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

605 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

550 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

StemTek Therapeutics is a start-up biotechnolgy company dedicated to accelerating drug discovery in cancer using cutting edge technology, world-class science and a stem cell centric point of view for cancer therapy. Our mission is to help design novel treatments for cancer targeting cancer stem cells.

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Working at the frontier of microfluidics, automation and machine learning to accelerate cell-based medicines. Scaled Biolabs accelerates the discovery and development of complex cell-based medicines, such as stem cell therapies and cancer immunotherapies. Their full stack optimization engine reduces complexity and time to market, by leveraging high-throughput, micro-scale cell culture, automation, and deep data insight. It also powers internal, grant funded programs such as developing a new gold standard for manufacturing dopaminergic neurons to treat Parkinson’s disease. Microfluidics, Biomedical R&D, Bioreactor, Single-cell Biology, Bioengineering, Stem Cells, Tissue Engineering, Cell Culture, Cell-based Assays, machine learning, and computer vision

88 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Image Processing A.I. Synthetic Biology A.I. - Machine Learning

Mapping the universe of biology 🧬 NanoString Technologies, a Bruker Company, is a provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression …

13 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory

376 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity.

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GDTM, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer. Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, …

57 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

226 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details. Stem Cell Research, Biotechnology, and High Throughput Stemcell Research

102 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBio Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications. contact@partitionbio.co.uk

328 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

410 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

170 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology